Compare Realty Income Corp (O) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs TG Therapeutics Inc — how do they compare? Realty Income Corp trades at $60.33 (market cap $57.74B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Realty Income Corp is far larger — about 6.8× TG Therapeutics Inc's market cap, and Realty Income Corp pays a 5.33% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| O | TGTX | |
|---|---|---|
Market Cap | $57.74B | $8.53B |
Sector | Real Estate | Health |
52-Week High | $67.56 | $59.06 |
52-Week Low | $55.93 | $26.94 |
Enterprise Value | $88.37B | $8.74B |
Dividend Yield | 5.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $61.02, down 0.38% with a bearish technical signal. The REIT maintains strong fundamentals with 92.6% gross margins and consistent dividend growth, recently increasing its monthly payout to $0.2715. However, the stock has missed earnings expectations for three consecutive quarters, and technical indicators show selling pressure with support at $60-61 levels. The company's $68.8 billion asset base supports its 5.3% dividend yield while debt levels have been trending upward.
O offers income investors a reliable dividend aristocrat with 25+ years of growth, but faces headwinds from interest rate sensitivity and recent earnings misses. The consensus price target of $66.50 suggests 9% upside potential, though technical weakness and rising debt-to-asset ratios warrant caution. The stock's appeal hinges on its ability to maintain AFFO growth amid a challenging rate environment.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
